Advancing Tomorrow’s Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development
Related Posts
Shitole SG, Chen E, Naveed M, Xue X, Sharma A, Hanna DB, Anastos K, Kaplan RC, Levsky JM, Tien PC, Radparvar AA, Bortnick AE, Budoff[...]
Yang JC, Situ J, Troutman R, Zhu R, Black M, Buri H, Gutta A, Tian F, Kang A, Aja E, Zeng A, Lai RW, Tan[...]
Shree S, Pike M, Yee LM, Levine L, Simhan H, Silver RM, Greenland P, Saade G, Bairey Merz CN, Chung J, Cleary EM, Grobman W,[...]